TN 201
Alternative Names: TN-201Latest Information Update: 10 Apr 2025
At a glance
- Originator Tenaya Therapeutics
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene transference; Myosin-binding protein C replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Hypertrophic cardiomyopathy
Most Recent Events
- 31 Mar 2025 Efficacy data from a phase-I/II clinical trials in Hypertrophic cardiomyopathy released by Tenaya Therapeutics
- 24 Mar 2025 Pharmacodynamics data from the preclinical trial in Hypertrophic cardiomyopathy released by Tenaya Therapeutics
- 17 Dec 2024 Pharmacodynamics, efficacy and adverse events data from a phase I/II trial in Hypertorphic cardiomyopathy released by Tenaya Therapeutics